Un estudio que evalúa atezolizumab, con o sin bevacizumab, en pacientes con carcinoma hepatocelular irresecable y cirrosis Child-Pugh B7 y B8 (Kirros)
Un estudio de fase II, abierto, de múltiples cohortes y multicéntrico en pacientes con carcinoma hepatocelular irresecable y cirrosis Child-Pugh B7 y B8
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
This is a Phase II, open-label, multicohort, multicenter study in participants with unresectable, locally advanced, or metastatic HCC who have Child-pugh B7 or B8 liver cirrhosis and have received no prior systemic therapy in this treatment setting. The study is designed to non-comparatively evaluate the safety of atezolizumab plus bevacizumab (Cohort A) or atezolizumab monotherapy (Cohort B) in this population.
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85724
- University of Arizona Cancer Center
-
-
California
-
La Jolla, California, Estados Unidos, 92093
- UC San Diego Moores Cancer Center
-
Los Angeles, California, Estados Unidos, 90089-5601
- University of Southern California-Keck School of Medicine -1975 Zonal Ave
-
Newport Beach, California, Estados Unidos, 92663
- University of Southern California
-
Orange, California, Estados Unidos, 92868
- University of California Irvine Medical Center
-
Pasadena, California, Estados Unidos, 91105-2561
- California Liver Research Institute
-
Sacramento, California, Estados Unidos, 95817
- University of California Davis Medical Center
-
Stanford, California, Estados Unidos, 94305
- Stanford Health Care
-
Torrance, California, Estados Unidos, 90502-2006
- Harbor UCLA Medical Center
-
West Hollywood, California, Estados Unidos, 90048-2422
- Cedars Sinai Comprehensive Transplant Center
-
-
Connecticut
-
Hartford, Connecticut, Estados Unidos, 06106
- Hartford Healthcare Cancer Institute at Hartford Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20037
- George Washington University- Medical Faculty Associates
-
Washington D.C., District of Columbia, Estados Unidos, 20422-0001
- Washington DC VA Medical Center
-
-
Florida
-
Orlando, Florida, Estados Unidos, 32806
- Orlando Health Inc.
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611-2908
- Northwestern University
-
Chicago, Illinois, Estados Unidos, 60612-4795
- University of Illinois Health Outpatient Care Center
-
Chicago, Illinois, Estados Unidos, 60637-1426
- The Duchossois Center for Advanced Medicine
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40536-7001
- University of Kentucky - Markey Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Estados Unidos, 70805
- LSU Health Baton Rouge
-
Baton Rouge, Louisiana, Estados Unidos, 70808-4300
- Our Lady of the Lake Cancer Institute
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, Estados Unidos, 02111
- Tufts Medical Center
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201
- Barbara Ann Karmanos Cancer Institute
-
Detroit, Michigan, Estados Unidos, 48202
- Henry Ford Health System
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64111
- Saint Luke?s Hospital of Kansas City
-
-
New Jersey
-
New Brunswick, New Jersey, Estados Unidos, 08901
- Rutgers Cancer Institute of New Jersey
-
Newark, New Jersey, Estados Unidos, 07103
- Rutgers Cancer Institute of New Jersey at University Hospital
-
-
New York
-
Mineola, New York, Estados Unidos, 11501-4064
- NYU Langone Hospital - Long Island
-
New York, New York, Estados Unidos, 10029
- Icahn School of Medicine at Mount Sinai
-
The Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center
-
The Bronx, New York, Estados Unidos, 10468-3904
- James J Peters Veterans Administration Medical Center - NAVREF
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28204
- Levine Cancer Institute
-
-
Ohio
-
Dayton, Ohio, Estados Unidos, 45428-9000
- Dayton VA Medical Center - NAVREF - PPDS
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104-5020
- The University of Oklahoma Health Sciences Center
-
-
Oregon
-
Hillsboro, Oregon, Estados Unidos, 97124-5806
- Kaiser Permanente Westside Medical Center
-
Portland, Oregon, Estados Unidos, 97239-3011
- OHSU Knight Cancer Institute Hematology Oncology
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19107
- Jefferson Health Honickman Center
-
Pittsburgh, Pennsylvania, Estados Unidos, 15240
- Veterans Affairs Pittsburgh Healthcare System - NAVREF - PPDS
-
-
Tennessee
-
Germantown, Tennessee, Estados Unidos, 38138-1762
- The West Clinic (East Campus)
-
Nashville, Tennessee, Estados Unidos, 37208-2918
- Nashville General Hospital at Meharry
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390-0001
- University of Texas Southwestern Medical Center
-
Dallas, Texas, Estados Unidos, 75246-2008
- Texas Oncology (Worth) - USOR
-
Dallas, Texas, Estados Unidos, 75203-1260
- Liver Institute at Methodist Dallas
-
Dallas, Texas, Estados Unidos, 75235
- Moody Outpatient Center ? Parkland Health
-
Denison, Texas, Estados Unidos, 75020-0084
- Texas Oncology - Denison Cancer Center
-
Houston, Texas, Estados Unidos, 77025-1669
- Kelsey Research Foundation
-
Houston, Texas, Estados Unidos, 77030-4211
- Michael E Debakey VA Medical Center - NAVREF - PPDS
-
-
Utah
-
Murray, Utah, Estados Unidos, 84107-5741
- Intermountain Healthcare
-
St. George, Utah, Estados Unidos, 84790
- Intermountain Cancer Center
-
-
Virginia
-
Falls Church, Virginia, Estados Unidos, 22042
- Inova Schar Cancer Institute
-
Richmond, Virginia, Estados Unidos, 23226-1925
- Bon Secours St. Mary's Hospital
-
Richmond, Virginia, Estados Unidos, 23298-5028
- VCU Medical Center North Hospital
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98101
- Virginia Mason Medical Center
-
-
-
-
-
Rio Piedras, Puerto Rico, 00935
- Pan American Center for Oncology Trials, LLC
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
General Inclusion Criteria:
- Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic participants
- Disease that is not amenable to curative surgical and/or locoregional therapies
- No prior systemic treatment (including systemic investigational agents) for locally advanced or metastatic and/or unresectable HCC
- Measurable disease (at least one untreated target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 7 days prior to initiation of study treatment
- Child-pugh B7 or B8 cirrhosis at screening and within 7 days prior to study treatment
- Adequate hematologic and end-organ function
- Life expectancy of at least 12 weeks
- Female participants of childbearing potential must be willing to avoid pregnancy and egg donation
- Absolute neutrophil count (ANC) ≥1.0 x 10^9 per liter (/L) (≥1000 per microliter [/μL]) without granulocyte colony-stimulating factor support
- Platelet count ≥ 50 × 109/L (50,000/μL) without transfusion
- Hemoglobin (Hb) ≥ 80 grams per liter (g/L) (8 grams per deciliter [g/dL])
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × upper limit of normal (ULN)
- Serum bilirubin ≤ 3 × ULN
- Creatinine clearance ≥ 50 milliliters per minute (mL/min) (calculated using the Cockcroft-gault formula)
- Serum albumin ≥ 20 g/L (2.0 g/dL) without transfusion in the prior 3 months
- International normalized ratio (INR) ≤2.3
General Exclusion Criteria:
- Pregnancy or breastfeeding
- Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies
- Treatment with investigational therapy within 28 days prior to initiation of study treatment
- Treatment with locoregional therapy to liver within 28 days prior to initiation of study treatment, or non-recovery from side effects of any such procedure
- Treatment with systemic immunostimulatory agents
- Treatment with systemic immunosuppressive medication
- Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment
- Inadequately controlled hypertension
- Active or history of autoimmune disease or immune deficiency
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
- Participants who have a known concurrent malignancy that is progressing or requires active treatment, who have not completely recovered from treatment, or who have a significant malignancy history that, in the opinion of the investigator, should preclude participation
- Participants on preventative hormonal therapies (i.e., tamoxifen and other hormonal inhibitors) are not excluded
- Known fibrolamellar HCC, sarcomatoid HCC, other rare HCC variant, or mixed cholangiocarcinoma and HCC
- Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
- Prior allogeneic stem cell or solid organ transplantation
- Actively listed for liver transplantation
- Co-infection with hepatitis B virus (HBV) and hepatitis C virus (HCV)
- Untreated or incompletely treated esophageal and/or gastric varices with bleeding or that are at high risk for bleeding
- A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment
- Grade ≥3 hemorrhage or bleeding event within 6 months prior to initiation of study treatment
- Hepatic encephalopathy is allowed if no active symptoms or stable within 3 months of study treatment
- History, planned, or recommended placement of transjugular intrahepatic portosystemic shunt (TIPS) is excluded from Cohort A only. TIPS is acceptable in Cohort B
- Diagnostic paracentesis is allowed. Therapeutic paracentesis: one large volume paracentesis prior to enrollment with diuretic controlled ascites is allowed.
- Participants with ascites controlled on diuretics are allowed
- History of spontaneous bacterial peritonitis within last 12 months
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Cohort A: Atezolizumab+Bevacizumab
Participants will receive atezolizumab plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator. |
Atezolizumab will be administered at a dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
Otros nombres:
Bevacizumab will be administered at a dose of 15 milligrams per kilogram (mg/kg) by IV infusion on Day 1 of each 21-day cycle.
Otros nombres:
|
|
Experimental: Cohort B: Atezolizumab
Participants will receive atezolizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator. |
Atezolizumab will be administered at a dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of Participants With Adverse Events (AEs)
Periodo de tiempo: Baseline through the end of the study (up to approximately 36 months)
|
An AE is any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Severity is determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0) in Cohorts A and B. |
Baseline through the end of the study (up to approximately 36 months)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: Clinical Trials, Hoffmann-La Roche
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- Carcinoma hepatocelular
- CHC
- Inmunoterapia
- Bevacizumab
- Atezolizumab
- Cirrosis
- Enfermedad del higado
- Cáncer de hígado
- Avastin
- Hígado graso
- CPB
- Genentech
- Tecentriq
- Neoplasias del Sistema Digestivo
- Inhibidor del punto de control inmunitario
- Kirros
- ML44719
- CPB 7
- CPB 8
- Hígado cirrótico
- Tumor Hepático
- Child-Pugh B
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Neoplasias por sitio
- Neoplasias
- Neoplasias por tipo histológico
- Enfermedades del Sistema Digestivo
- Neoplasias Glandulares y Epiteliales
- Adenocarcinoma
- Carcinoma
- Condiciones Patológicas, Signos y Síntomas
- Carcinoma Hepatocelular
- Neoplasias Hepaticas
- Fibrosis
- Enfermedades del HIGADO
- Hígado graso
- Neoplasias del Sistema Digestivo
- Aminoácidos, péptidos y proteínas
- Proteínas
- Anticuerpos, monoclonales, humanizados
- Anticuerpos, monoclonal
- Anticuerpos
- Inmunoglobulinas
- Inmunoproteínas
- Proteínas de la sangre
- Globulinas séricas
- Globulinas
- Bevacizumab
- atezolizumab
Otros números de identificación del estudio
Otros números de identificación del estudio
- ML44719
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .